FDA Brief

Warning letters Drugs

FDA warning letter to

Sanitor Corporation

High riskIssued Nov 29, 2021Posted Dec 14, 2021Division of Pharmaceutical Quality Operations IV

Sanitor Corporation was cited for CGMP violations after hand sanitizer failed microbial testing and skin-bleaching drugs were sold without approval.

What happened

FDA inspected Sanitor Corporation's drug manufacturing facility in Stanton, California, from May 25, 2021, to June 3, 2021. Investigators found multiple hand sanitizer batches failed microbial total plate count testing with "Too Numerous to Count" results, and the quality unit approved adding a preservative and released batches, including one shipped before microbiological results were received. FDA also cited unapproved skin-bleaching/lightening drug products, misbranding, and failure to list hydroquinone products.

What FDA found

  1. The quality unit did not adequately investigate hand sanitizer batches that failed microbial testing, allowed preservative to be added to failed or untested batches, and approved a shipment before microbiological results were available.

    21 CFR 211.22
  2. The company released reworked and reformulated hand sanitizer without demonstrating the antimicrobial effectiveness of the added preservative.

    21 CFR 211.160(b)
  3. The stability program was inadequate, including an unsupported bracketing approach for hydroquinone products implemented without adequate change control.

    21 CFR 211.22
  4. Batch records were not recorded contemporaneously, and a verifier was documented as present when they were not at work.

    21 CFR 211.22
  5. The FTIR spectroscopy computer system lacked controls to prevent deletion of raw data and lacked adequate password protection.

    21 CFR 211.68(b)
  6. Skin bleaching/lightening products were marketed as unapproved new drugs, an acne treatment was misbranded, and hydroquinone products were not listed with FDA.

    FD&C Act sections 505(a), 502(c), 510(j)

What FDA wants

FDA asks the company to provide comprehensive independent assessments, investigations, CAPA plans, and remediation for its quality, laboratory, stability, documentation, and data-integrity systems, and to take rapid corrective action if its hand sanitizer review finds failing products were distributed. The provided letter text does not state a response deadline.

Who should pay attention

  • companies that buy hand sanitizer from contract manufacturers
  • brands selling skin-lightening or hydroquinone products
  • quality teams at OTC drug contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk